Payment overview · 2025
General Payments
$429.25
18 reported records · 10 companies
Healthcare provider profile · identity verified
Daniel Aaron Stegman
Allopathic & Osteopathic Physicians|Family Medicine · TULSA, OK · NPI 1396249082
Verified facts
What the public records show
CMS Open Payments records show Daniel Aaron Stegman received $429.25 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Kerendia, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $167.33 | 39.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.69 | 14.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.47 | 11.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.43 | 7.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.87 | 7.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.95 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.55 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.76 | 3.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.06 | 3.5% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $14.14 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $429.25 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $134.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $78.02 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.47 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.47 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.87 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 546 | 175 |
| Lisinopril | Lisinopril | 447 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 107 |
| Losartan Potassium | Losartan Potassium | 291 | 91 |
| Gabapentin | Gabapentin | 244 | 70 |
| Potassium Chloride | Potassium Chloride | 244 | 76 |
| Trazodone Hcl | Trazodone Hcl | 230 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 66 |
| Metformin Hcl | Metformin Hcl | 200 | 60 |
| Furosemide | Furosemide | 195 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 63 |
| Omeprazole | Omeprazole | 185 | 55 |
| Carvedilol | Carvedilol | 182 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 164 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 64 |
| Ozempic | Semaglutide | 149 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 45 |
| Farxiga | Dapagliflozin Propanediol | 137 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 39 |
| Famotidine | Famotidine | 135 | 53 |
| Meloxicam | Meloxicam | 125 | 37 |
| Tramadol Hcl | Tramadol Hcl | 123 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 21 |
| Alprazolam | Alprazolam | 115 | 20 |
| Eliquis | Apixaban | 108 | 22 |
| Montelukast Sodium | Montelukast Sodium | 108 | 29 |
| Jardiance | Empagliflozin | 105 | 20 |
| Simvastatin | Simvastatin | 103 | 28 |
| Ezetimibe | Ezetimibe | 97 | 37 |
| Sertraline Hcl | Sertraline Hcl | 90 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 27 |
| Allopurinol | Allopurinol | 79 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 25 |
| Celecoxib | Celecoxib | 77 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 60 |
| Buspirone Hcl | Buspirone Hcl | 70 | 22 |
| Finasteride | Finasteride | 70 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 22 |
| Topiramate | Topiramate | 61 | 18 |
| Alendronate Sodium | Alendronate Sodium | 60 | 21 |
| Donepezil Hcl | Donepezil Hcl | 60 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 20 |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 21 |
| Glipizide | Glipizide | 57 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 16 |
| Spironolactone | Spironolactone | 54 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 47 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 14 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Sucralfate | Sucralfate | 48 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 17 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Temazepam | Temazepam | 43 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 42 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 12 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Atenolol | Atenolol | 38 | 11 |
| Glipizide Er | Glipizide | 37 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 12 |
| Ketoconazole | Ketoconazole | 35 | 16 |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 24 |
| Azelastine Hcl | Azelastine Hcl | 31 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 23 |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Naproxen | Naproxen | 27 | 12 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Trospium Chloride | Trospium Chloride | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Nystatin | Nystatin | 19 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Quviviq | Daridorexant Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Prednisone | Prednisone | 17 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $429.25 · 18 records | Lilly USA, LLC | ABRYSVO, CAPLYTA, COLLAGENASE SANTYL, COMIRNATY, Cologuard Collection Kit, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, PREVNAR 20, Veozah, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error